Literature DB >> 17341858

PsoReg--the Swedish registry for systemic psoriasis treatment. The registry's design and objectives.

Marcus Schmitt-Egenolf1.   

Abstract

With the introduction of new systemic drugs for the management of psoriasis, we felt an obligation in Sweden to establish a trusted tool to monitor their use. We formed PsoReg to create a solid, long-term database in order to analyze safety and effectiveness of different systemic psoriasis treatment regimens. PsoReg will provide information to help clinicians individualize therapy on a rational basis through evaluation of effectiveness and adverse effects in specific patient subgroups. Designed and managed by specialized health care professionals, PsoReg will enroll all psoriasis patients on systemic treatment to allow a fair comparison of old versus new-generation psoriasis treatments. PsoReg will even create benchmark data for quality assurance of the medical service. A web-based design allows real-time pharmacovigilance and enables the registry to assist clinicians in their day-to-day management of psoriasis patients. In this way PsoReg can become an integrated part of tomorrow's dermatology. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17341858     DOI: 10.1159/000098568

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  9 in total

1.  Development of an Inflammatory Bowel Disease Research Registry Derived from Observational Electronic Health Record Data for Comprehensive Clinical Phenotyping.

Authors:  Alyce J M Anderson; Benjamin Click; Claudia Ramos-Rivers; Dmitriy Babichenko; Ioannis E Koutroubakis; Douglas J Hartman; Jana G Hashash; Marc Schwartz; Jason Swoger; Arthur M Barrie; Michael A Dunn; Miguel Regueiro; David G Binion
Journal:  Dig Dis Sci       Date:  2016-09-12       Impact factor: 3.199

Review 2.  Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: A systematic and critical review.

Authors:  Sue Langham; Julia Langham; Hans-Peter Goertz; Mark Ratcliffe
Journal:  BMC Med Res Methodol       Date:  2011-03-31       Impact factor: 4.615

3.  Impact of Bariatric Surgery on Moderate to Severe Psoriasis: A Retrospective Nationwide Registry Study.

Authors:  Marta Laskowski; Linus Schiöler; Johan Ottosson; Marcus Schmitt-Egenolf; Ann-Marie Wennberg; Torsten Olbers; Kjell Torén; Helena Gustafsson
Journal:  Acta Derm Venereol       Date:  2021-06-30       Impact factor: 3.875

4.  Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients.

Authors:  Paul S Calara; Rikard Althin; Katarina Steen Carlsson; Marcus Schmitt-Egenolf
Journal:  BioDrugs       Date:  2017-02       Impact factor: 5.807

5.  Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.

Authors:  David Hägg; Anders Sundström; Marie Eriksson; Marcus Schmitt-Egenolf
Journal:  Am J Clin Dermatol       Date:  2017-08       Impact factor: 7.403

6.  How is disease severity associated with quality of life in psoriasis patients? Evidence from a longitudinal population-based study in Sweden.

Authors:  Kirk Geale; Martin Henriksson; Marcus Schmitt-Egenolf
Journal:  Health Qual Life Outcomes       Date:  2017-07-28       Impact factor: 3.186

7.  Sequential Multiple Imputation for Real-World Health-Related Quality of Life Missing Data after Bariatric Surgery.

Authors:  Sun Sun; Nan Luo; Erik Stenberg; Lars Lindholm; Klas-Göran Sahlén; Karl A Franklin; Yang Cao
Journal:  Int J Environ Res Public Health       Date:  2022-08-30       Impact factor: 4.614

8.  The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men.

Authors:  David Hägg; Marie Eriksson; Anders Sundström; Marcus Schmitt-Egenolf
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

9.  Evaluation of Neopterin Level and Disease Severity in Patients with Psoriasis Vulgaris Treated with Narrowband UVB.

Authors:  Funda Kemeriz; Müzeyyen Gönül; Fatma Pelin Cengiz; Nazan Emiroğlu; Bengü Çevirgen Cemil
Journal:  Indian J Dermatol       Date:  2019 Nov-Dec       Impact factor: 1.494

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.